MedinCell S.A.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceuti…
Biotechnology
FR, Jacou [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 25.54 | -18.41 | -24.72 | |
| Graham Fair Price | 81.13 | 4.47 | 2.47 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | 3.92 | -6.66 | -6.93 | |
| Price/Cash Flow | inf | 0.00 | -13.18 | |
| Prices/Earnings | 26.37 | -4.02 | -5.47 | |
| Price/Sales | 419.84 | 132.72 | 25.53 | |
| Price/FCF | inf | 0.00 | -13.18 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -14.61 | 1.00 | 1.17 | |
| Operating Margin | -359.98 | -6.69 | -1.46 | |
| ROA | -182.74 | -0.46 | -0.16 | |
| ROE | 0.32 | 0.41 | 30.50 | |
| ROIC | -0.25 | 0.31 | 21.24 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 0.00 | 0.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | 0.00 | 0.00 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | < 0.005 | 0.00 | inf | |
| Days Sales Outstanding (DSO) | 141.91 | 0.00 | inf | |
| Inventory Turnover | -1195000.00 | 0.00 | inf | |
| Debt/Capitalization | 1.73 | 0.00 | inf | |
| Quick Ratio | 1.91 | 1.18 | -38.02 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.92 | -1.47 | -58.56 | |
| Cash | 0.96 | 0.70 | -27.33 | |
| Capex | -0.01 | n.A. | n.A. | |
| Free Cash Flow | -0.49 | n.A. | n.A. | |
| Revenue | 0.25 | 0.07 | -70.69 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Weak